

## Form 605

Corporations Act 2001  
Section 671B

## Notice of ceasing to be a substantial holder

**To Company Name/Scheme**

Alterity Therapeutics Ltd

**ACN/ARSN/ABN**

37 080 699 065

**1. Details of substantial holder (1)****Name**

JPMorgan Chase &amp; Co. and its affiliates

**ACN/ARSN (if applicable)**

NA

The holder ceased to be a substantial holder on 04/February/2025

The previous notice was given to the company on 05/February/2025

The previous notice was dated 03/February/2025

**2. Changes in relevant interests**

Particulars of each change in, or change in the nature of, a relevant interest (2) of the substantial holder or an associate (3) in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

Date of change	Person whose relevant interest changed	Nature of change (4)	Consideration given in relation to change (5)	Class (6) and number of securities affected	Person's votes affected
See Appendix	J.P. MORGAN SECURITIES LLC	Holder of securities subject to an obligation to return under a securities lending agreement	See Appendix	15,480,000 (Ordinary)	15,480,000 (Ordinary)
See Appendix	J.P. MORGAN SECURITIES LLC	Rehypotheication of client securities under a Prime Brokerage Agreement	See Appendix	19,512,000 (Ordinary)	19,512,000 (Ordinary)
See Appendix	J.P. MORGAN SECURITIES AUSTRALIA LIMITED	Purchase and sales of securities in its capacity as Principal/Proprietary	See Appendix	15,029 (Ordinary)	15,029 (Ordinary)
See Appendix	J.P. MORGAN PRIME INC.	Rehypotheication of client securities under a Prime Brokerage Agreement	See Appendix	289,200 (Ordinary)	289,200 (Ordinary)

**3. Changes in association**

The persons who have become associates (3) of, ceased to be associates of, or have changed the nature of their association (7) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

Name and ACN/ARSN (if applicable)	Nature of association
J.P. MORGAN SECURITIES AUSTRALIA LIMITED	Subsidiary of JPMorgan Chase & Co.
J.P. MORGAN SECURITIES LLC	Subsidiary of JPMorgan Chase & Co.
J.P. MORGAN PRIME INC.	Subsidiary of JPMorgan Chase & Co.

**4. Addresses**

The addresses of persons named in this form are as follows:

Name	Address
JPMorgan Chase & Co.	383 Madison Avenue, New York, New York, NY, 10179, United States
J.P. MORGAN SECURITIES AUSTRALIA LIMITED	LEVEL 18, 83-85 CASTLEREAGH STREET, SYDNEY, NSW 2000, Australia
J.P. MORGAN SECURITIES LLC	383 Madison Ave., New York, New York, NY, 10179, United States
J.P. MORGAN PRIME INC.	383 Madison Avenue, New York, New York, NY, 10179, United States

**Signature**

Print name      S. Seshagiri Rao      Capacity      Compliance Officer

---

Sign here      *S. Seshagiri Rao*      Date      06/February/2025

---

---

---

**DIRECTIONS**

- (1) If there are a number of substantial holders with similar or related relevant interests (e.g. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 4 of the form.
- (2) See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.
- (3) See the definition of "associate" in section 9 of the Corporations Act 2001.
- (4) Include details of:
  - (a) any relevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
  - (b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).

See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.

- (5) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.
  - (6) The voting shares of a company constitute one class unless divided into separate classes.
  - (7) Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice.
-

TRADES FOR RELEVANT PERIOD							Appendix
Transaction Date	Entity	Product Type	Type of Transaction	Quantity	Price (AUD)	Consideration	
<b>Balance at start of relevant period</b>				<b>272,198,215</b>			
4-Feb-25	J.P. MORGAN SECURITIES LLC	Depository Receipt	Borrow Return	(600,000)	-	\$ -	
4-Feb-25	J.P. MORGAN SECURITIES LLC	Depository Receipt	Borrow Return	(9,300,000)	-	\$ -	
4-Feb-25	J.P. MORGAN SECURITIES LLC	Depository Receipt	Borrow Return	(5,580,000)	-	\$ -	
4-Feb-25	J.P. MORGAN PRIME INC.	Depository Receipt	On-Lend	289,200	-	\$ -	
4-Feb-25	J.P. MORGAN SECURITIES LLC	Depository Receipt	On-Lend Return	(19,512,000)	-	\$ -	
4-Feb-25	J.P. MORGAN SECURITIES AUSTRALIA LIMITED	Equity	Buy	15,029	0.01	\$ 202.89	
<b>Balance at end of relevant period</b>				<b>237,510,444</b>			